Flavophospholipol use in animals : Positive implications for antimicrobial resistance based on its microbiologic propertiesPFALLER, Michael A.Diagnostic microbiology and infectious disease. 2006, Vol 56, Num 2, pp 115-121, issn 0732-8893, 7 p.Article

Rapid Detection of Antibiotic-Resistant Organism Carriage for Infection PreventionDIEKEMA, Daniel J; PFALLER, Michael A.Clinical infectious diseases. 2013, Vol 56, Num 11, pp 1614-1620, issn 1058-4838, 7 p.Article

Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamasesPFALLER, Michael A; SEGRETI, John.Clinical infectious diseases. 2006, Vol 42, issn 1058-4838, S153-S163, SUP4Article

Gatifloxacin Phase IV Surveillance Trial (TeqCES Study) utilizing 5000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections : Symposium on the topic of gatifloxacin (TeqCES trial)PFALLER, Michael A; JONES, Ronald N.Diagnostic microbiology and infectious disease. 2002, Vol 44, Num 1, pp 77-84, issn 0732-8893, 8 p.Article

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin BreakpointsCAVLING ARENDRUP, Maiken; PFALLER, Michael A.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 7, pp 3965-3968, issn 0066-4804, 4 p.Article

Epidemiology of Invasive Mycoses in North AmericaPFALLER, Michael A; DIEKEMA, Daniel J.Critical reviews in microbiology. 2010, Vol 36, Num 1, pp 1-53, issn 1040-841X, 53 p.Article

Has antifungal susceptibility testing come of age?REX, John H; PFALLER, Michael A.Clinical infectious diseases. 2002, Vol 35, Num 8, pp 982-989, issn 1058-4838, 8 p.Article

Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infectionsPFALLER, Michael A; SUTTON, Deanna A.Diagnostic microbiology and infectious disease. 2006, Vol 56, Num 2, pp 147-152, issn 0732-8893, 6 p.Article

Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicansCHATURVEDI, Vishnu; RAMANI, Rama; PFALLER, Michael A et al.Journal of clinical microbiology (Print). 2004, Vol 42, Num 5, pp 2249-2251, issn 0095-1137, 3 p.Article

Flucytosine resistance is restricted to a single genetic clade of Candida albicansPUJOL, Claude; PFALLER, Michael A; SOLL, David R et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 1, pp 262-266, issn 0066-4804, 5 p.Article

Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000PFALLER, Michael A; JONES, Ronald N.International journal of antimicrobial agents. 2002, Vol 19, Num 5, pp 383-388, issn 0924-8579Article

Ciprofloxacin as broad-spectrum empiric therapy: are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US)?JONES, Ronald N; PFALLER, Michael A.Diagnostic microbiology and infectious disease. 2002, Vol 42, Num 3, pp 213-215, issn 0732-8893Article

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? : Report from the SENTRY Antimicrobial Surveillance Program (1997-99)JONES, Ronald N; PFALLER, Michael A.Diagnostic microbiology and infectious disease. 2001, Vol 39, Num 4, pp 237-243, issn 0732-8893Article

Improving typeability of multiple bacterial species using pulsed-field gel electrophoresis and thioureaSILBERT, Suzane; BOYKEN, Linda; HOLLIS, Richard J et al.Diagnostic microbiology and infectious disease. 2003, Vol 47, Num 4, pp 619-621, issn 0732-8893, 3 p.Article

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance : Data from the SENTRY Antimicrobial Surveillance ProgramJONES, Ronald N; PFALLER, Michael A.Clinical infectious diseases. 2000, Vol 31, pp S16-S23, issn 1058-4838, SUP2Conference Paper

Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)PFALLER, Michael A; SADER, Helio S; JONESB, Ronald N et al.Diagnostic microbiology and infectious disease. 2007, Vol 57, Num 4, pp 459-465, issn 0732-8893, 7 p.Article

Contemporary tools for the diagnosis and management of invasive mycosesALEXANDER, Barbara D; PFALLER, Michael A.Clinical infectious diseases. 2006, Vol 43, issn 1058-4838, S15-S27, SUP1Article

Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory Surveillance Program study: Microbiology from the medical office practice environmentPFALLER, Michael A; EHRHARDT, Anton F; JONES, Ronald N et al.The American journal of medicine. 2001, Vol 111, Num 9A, pp 4S-12S, issn 0002-9343Article

Modification of Dienes mutual inhibition test for epidemiological characterization of Pseudomonas aeruginosa isolatesMUNSON, Erik L; PFALLER, Michael A; DOERN, Gary V et al.Journal of clinical microbiology (Print). 2002, Vol 40, Num 11, pp 4285-4288, issn 0095-1137, 4 p.Article

Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different!JONES, Ronald N; BEACH, Mondell L; PFALLER, Michael A et al.Diagnostic microbiology and infectious disease. 2001, Vol 41, Num 3, pp 161-163, issn 0732-8893Article

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory ConcentrationsALEXANDER, Barbara D; JOHNSON, Melissa D; PFEIFFER, Christopher D et al.Clinical infectious diseases. 2013, Vol 56, Num 12, pp 1724-1732, issn 1058-4838, 9 p.Article

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteriaPFALLER, Michael A; ANDES, David; JOHNSON, Elizabeth M et al.Diagnostic microbiology and infectious disease. 2011, Vol 70, Num 3, pp 330-343, issn 0732-8893, 14 p.Article

Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of CandidaPFALLER, Michael A; CASTANHEIRA, Mariana; DIEKEMA, Daniel J et al.Journal of clinical microbiology (Print). 2011, Vol 49, Num 11, pp 3800-3804, issn 0095-1137, 5 p.Article

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methodsPFALLER, Michael A; BOYKEN, Linda; HOLLIS, Richard J et al.Diagnostic microbiology and infectious disease. 2010, Vol 67, Num 1, pp 56-60, issn 0732-8893, 5 p.Article

Screening of a Large Global Aspergillus fumigatus Species Complex Collection by Using a Species-Specific Microsphere-Based Luminex AssayETIENNE, Kizee A; GADE, Lalitha; LOCKHART, Shawn R et al.Journal of clinical microbiology (Print). 2009, Vol 47, Num 12, pp 4171-4172, issn 0095-1137, 2 p.Article